Published in J Biol Chem on April 08, 2015
p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget (2015) 0.82
Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. World J Gastroenterol (2016) 0.79
PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape. J Cell Sci (2015) 0.76
Group I Paks promote skeletal myoblast differentiation in vivo and in vitro. Mol Cell Biol (2016) 0.75
Pak4 Is Required during Epithelial Polarity Remodeling through Regulating AJ Stability and Bazooka Retention at the ZA. Cell Rep (2016) 0.75
RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6. Dev Cell (2017) 0.75
Cross-talk between p21-activated kinase 4 and ERα signaling triggers endometrial cancer cell proliferation. Oncotarget (2017) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 13.85
The conformational plasticity of protein kinases. Cell (2002) 11.21
Rho GTPases and their effector proteins. Biochem J (2000) 8.89
Biology of the p21-activated kinases. Annu Rev Biochem (2003) 7.63
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell (2004) 6.92
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell (2000) 4.21
enoLOGOS: a versatile web tool for energy normalized sequence logos. Nucleic Acids Res (2005) 4.03
A proteome-scale map of the human interactome network. Cell (2014) 3.91
A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol (2006) 3.40
A tale of two Paks. Biol Cell (2008) 2.90
Substrate competition as a source of ultrasensitivity in the inactivation of Wee1. Cell (2007) 2.88
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res (2014) 2.66
PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J (1998) 2.62
p21-activated kinases: three more join the Pak. Int J Biochem Cell Biol (2002) 2.61
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem (2001) 2.07
Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. EMBO J (2005) 2.02
Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell (2002) 2.00
The genetics of Pak. J Cell Sci (2004) 2.00
The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity. J Biol Chem (2001) 1.96
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A (2010) 1.94
Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem (2001) 1.93
Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J Biol Chem (2007) 1.92
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem (2001) 1.78
PAK4 mediates morphological changes through the regulation of GEF-H1. J Cell Sci (2005) 1.75
Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat Struct Biol (2000) 1.65
AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol (2002) 1.60
Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. J Biol Chem (2001) 1.59
p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol (2003) 1.57
PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol Cell Biol (2003) 1.55
p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). J Biol Chem (2012) 1.55
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A (2010) 1.50
PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol (2002) 1.49
The emerging importance of group II PAKs. Biochem J (2010) 1.42
A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal (2008) 1.38
Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure (2007) 1.34
Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev (2009) 1.30
A single pair of acidic residues in the kinase major groove mediates strong substrate preference for P-2 or P-5 arginine in the AGC, CAMK, and STE kinase families. J Biol Chem (2005) 1.28
Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene (2002) 1.27
Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate (2008) 1.24
PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci (2002) 1.24
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol (2009) 1.23
PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci (2010) 1.17
Targeted disruption of the gene for the PAK5 kinase in mice. Mol Cell Biol (2003) 1.17
P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. J Cell Biol (2002) 1.17
p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway. Oncotarget (2014) 1.15
Identification of an autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem (2003) 1.15
Death receptor-induced activation of initiator caspase 8 is antagonized by serine/threonine kinase PAK4. Mol Cell Biol (2003) 1.13
Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO Rep (2012) 1.13
Role of p-21-activated kinases in cancer progression. Int Rev Cell Mol Biol (2014) 1.13
Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci U S A (2013) 1.12
Targeted disruption of the Pak5 and Pak6 genes in mice leads to deficits in learning and locomotion. Dev Biol (2008) 1.10
P21 activated kinases: structure, regulation, and functions. Small GTPases (2014) 1.06
Determinants for substrate phosphorylation by p21-activated protein kinase (gamma-PAK). Biochemistry (1997) 1.06
Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res (2012) 1.06
Essential role for the Pak4 protein kinase in extraembryonic tissue development and vessel formation. Mech Dev (2009) 1.05
Nucleo-cytoplasmic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Biochim Biophys Acta (2011) 1.05
Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol (2005) 1.05
LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett (2011) 1.04
Direct interaction of p21-activated kinase 4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. J Biol Chem (2003) 1.03
P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer (2009) 1.03
Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res (2011) 1.02
Inhibitors of p21-activated kinases (PAKs). J Med Chem (2014) 1.02
P21-activated kinase 4--not just one of the PAK. Eur J Cell Biol (2013) 0.99
Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proc Natl Acad Sci U S A (2012) 0.98
p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration. J Biol Chem (2010) 0.98
Integrin-mediated cell attachment induces a PAK4-dependent feedback loop regulating cell adhesion through modified integrin alpha v beta 5 clustering and turnover. Mol Biol Cell (2010) 0.98
PAK4 kinase-mediated SCG10 phosphorylation involved in gastric cancer metastasis. Oncogene (2013) 0.97
Structure of the complex of Cdc42Hs with a peptide derived from P-21 activated kinase. Biochemistry (2000) 0.97
Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate (2010) 0.97
Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. Mol Cell (2013) 0.96
p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem (2008) 0.96
Subgroup II PAK-mediated phosphorylation regulates Ran activity during mitosis. J Cell Biol (2010) 0.94
Dynamic architecture of a protein kinase. Proc Natl Acad Sci U S A (2014) 0.94
p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol (2010) 0.91
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. J Med Chem (2014) 0.90
Multiple Rho proteins regulate the subcellular targeting of PAK5. Biochem Biophys Res Commun (2006) 0.88
N-terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals. J Cell Physiol (2010) 0.88
Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma. Cancer Sci (2009) 0.87
Identification of neuronal substrates implicates Pak5 in synaptic vesicle trafficking. Proc Natl Acad Sci U S A (2012) 0.86
A PAK6-IQGAP1 complex promotes disassembly of cell-cell adhesions. Cell Mol Life Sci (2013) 0.84
p120-catenin is a binding partner and substrate for Group B Pak kinases. J Cell Biochem (2010) 0.83
PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene (2012) 0.83
NMR binding and crystal structure reveal that intrinsically-unstructured regulatory domain auto-inhibits PAK4 by a mechanism different from that of PAK1. Biochem Biophys Res Commun (2013) 0.82
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013) 0.81
Functional cross-talk between Cdc42 and two downstream targets, Par6B and PAK4. Biochem J (2015) 0.80
Substrate and inhibitor specificity of the type II p21-activated kinase, PAK6. PLoS One (2013) 0.78
Pak6 protein kinase is a novel effector of an atypical Rho family GTPase Chp/RhoV. Biochemistry (Mosc) (2012) 0.78